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IMPORTANCE Older and/or frail patients are underrepresented in landmark cancer trials.
Tailored research is needed to address this evidence gap.
OBJECTIVE The GO2 randomized clinical trial sought to optimize chemotherapy dosing in
older and/or frail patients with advanced gastroesophageal cancer, and explored baseline
geriatric assessment (GA) as a tool for treatment decision-making.
DESIGN, SETTING, AND PARTICIPANTS This multicenter, noninferiority, open-label randomized
trial took place at oncology clinics in the United Kingdom with nurse-led geriatric health
assessment. Patients were recruited for whom full-dose combination chemotherapy was
considered unsuitable because of advanced age and/or frailty.
INTERVENTIONS There were 2 randomizations that were performed: CHEMO-INTENSITY
compared oxaliplatin/capecitabine at Level A (oxaliplatin 130 mg/m2 on day 1, capecitabine
625 mg/m2 twice daily on days 1-21, on a 21-day cycle), Level B (doses 0.8 times A), or Level C
(doses 0.6 times A). Alternatively, if the patient and clinician agreed the indication for
chemotherapy was uncertain, the patient could instead enter CHEMO-BSC, comparing Level
C vs best supportive care.
MAIN OUTCOMES AND MEASURES First, broad noninferiority of the lower doses vs reference
(Level A) was assessed using a permissive boundary of 34 days reduction in progression-free
survival (PFS) (hazard ratio, HR = 1.34), selected as acceptable by a forum of patients and
clinicians. Then, the patient experience was compared using Overall Treatment Utility (OTU),
which combines efficacy, toxic effects, quality of life, and patient value/acceptability. For
CHEMO-BSC, the main outcome measure was overall survival.
RESULTS A total of 514 patients entered CHEMO-INTENSITY, of whom 385 (75%) were men
and 299 (58%) were severely frail, with median age 76 years. Noninferior PFS was confirmed
for Levels B vs A (HR = 1.09 [95% CI, 0.89-1.32]) and C vs A (HR = 1.10 [95% CI, 0.90-1.33]).
Level C produced less toxic effects and better OTU than A or B. No subgroup benefited from
higher doses: Level C produced better OTU even in younger or less frail patients. A total of 45
patients entered the CHEMO-BSC randomization: overall survival was nonsignificantly longer
with chemotherapy: median 6.1 vs 3.0 months (HR = 0.69 [95% CI, 0.32-1.48], P = .34). In
multivariate analysis in 522 patients with all variables available, baseline frailty, quality of life,
and neutrophil to lymphocyte ratio were independently associated with OTU, and can be
combined in a model to estimate the probability of different outcomes.
CONCLUSIONS AND RELEVANCE This phase 3 randomized clinical trial found that
reduced-intensity chemotherapy provided a better patient experience without significantly
compromising cancer control and should be considered for older and/or frail patients.
Baseline geriatric assessment can help predict the utility of chemotherapy but did not identify
a group benefiting from higher-dose treatment.
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C ancer is most common in older people. In North Americaand Europe, gastroesophageal cancer is the third mostcommon cause of cancer death, with more than half
these deaths in people over 75 years,1 many of whom are frail
and with comorbidities. But evidence guiding treatment for
vulnerable older patients is poor: standard chemotherapy regi-
mens were developed in trials involving predominantly non-
frail, noncomorbid patients of median age less than 65,2-5 and
although selected older people participated they cannot be as-
sumed to fully represent the older population.
In 2011, MRC FOCUS2,6 a national randomized trial de-
signed for frail and older patients with colorectal cancer, was
reported. It used reduced doses of chemotherapy and intro-
duced a novel composite end point, Overall Treatment Utility
(OTU), combining clinical efficacy, tolerability, and the pa-
tient’s own assessment of treatment value and acceptability.
In the same year we surveyed 50 gastrointestinal oncologists
in the UK7: 49 reported routinely treating older patients with
gastroesophageal cancer with standard schedules at reduced
doses, or omitting agents. There was wide variation in prac-
tice and no use of objective geriatric assessment (GA) to guide
decisions. This led to 321GO, a randomized feasibility trial in
which older and/or frail patients with gastroesophageal can-
cer received 80% doses of the standard 3-drug schedule epi-
rubicin/oxaliplatin/capecitabine (EOCap),2 the same treat-
ment omitting epirubicin (OCap), or the same treatment
omitting both epirubicin and oxaliplatin (Cap). The best bal-
ance of benefits and tolerability was achieved with the OCap
doublet.7 This trial allowed further development of the OTU
end point.7,8
The GO2 randomized clinical trial takes the OCap sched-
ule from 321GO7 and compares 3 dose levels, seeking the best
balance of efficacy and patient experience. For patients with
uncertainty regarding whether to use chemotherapy at all, an
alternative randomization compares the lowest dose level vs
supportive care alone. We ask whether a baseline GA may aid
personalized dose selection and perhaps identify patients un-
likely to benefit from chemotherapy. More broadly, GO2 aims
to stimulate researchers across all cancer types to evaluate pa-
tient-centered assessment, dosing, and outcome measure-
ment for vulnerable patients.
Methods
Study Design and Participants
The GO2 trial (ISRCTN44687907) was an academic,
multicenter, open-label randomized trial, approved by the UK
National Research Ethics Service, overseen by independent
Trial Steering and Data Monitoring & Ethics Committees. All
participants gave fully informed written consent. The study
is closed and follow-up is complete. The authors assume
responsibility for accuracy, completeness, and fidelity to the
trial protocol (Supplement 1) and statistical analysis plan
(Supplement 2).
Eligibility criteria are detailed in the Trial Protocol.
P at i e nt s h a d l o c a l l y a d v a n c e d a n d /o r m e t a s t at i c
gastroesophageal cancer that was not pretreated. In the
absence of established objective frailty thresholds, and
given the complex interrelations of frailty and advanced
age, we used oncologists’ clinical judgment in selecting
patients. The key eligibility criterion was that the oncologist
considered full-dose standard combination chemotherapy
(at that time epirubicin/oxaliplatin/capecitabine2 or
cisplatin/fluorouracil/trastuzumab9) unsuitable because of
the patient’s advanced age and/or frailty. It was made clear
to patients and clinicians that GO2 was a trial for older
patients, but there were no chronological age limits. Fur-
thermore, since scoring of performance status (PS) by
oncologists in older patients is inconsistent,10 a fixed PS
threshold was not specified, but patients had to be consid-
ered fit for any of the treatments in their selected random-
ization. Patients with moderate renal/hepatic dysfunction
could be entered with dose adjustment to compensate for
reduced clearance. Medical comorbidity was allowed pro-
vided the oncologist did not consider this to preclude che-
motherapy. Response Evaluation Criteria in Solid Tumors–
assessable disease was not mandatory.11
Randomization
If the clinician and/or patient considered chemotherapy
definitely indic ated, patients entered the CHEMO-
INTENSITY randomization and were allocated (1:1:1) to
OCap dose Level A, B, or C. Level A treatment was oxalipl-
atin 130 mg/m2 on day 1 and capecitabine 625 mg/m2 twice
daily on days 1-21, on a 21-day cycle; Level B treatment was
80% of Level A doses; and Level C treatment was 60% of
Level A doses. If the patient and clinician agreed that best
supportive care alone (BSC) would be an acceptable alterna-
tive, patients could instead enter the CHEMO-BSC random-
ization, with allocation (1:1) to OCap Level C or BSC. Ran-
domization used an automated telephone/web system and
validated minimization algorithm, with age, PS, metastases,
histology, renal function, planned trastuzumab use, and
center as stratification factors. The treatment allocation was
not masked from study investigators or patients.
Key Points
Question Do older and/or frail patients with advanced
gastroesophageal cancer benefit from less intensive palliative
chemotherapy, and can a formal geriatric assessment assist
treatment decision-making?
Findings This phase 3 randomized clinical trial including 559
patients with advanced gastroesophageal cancer found that
reducing the intensity of chemotherapy provided an improved
patient experience with no significant detriment in cancer control.
Baseline frailty, quality of life, and neutrophil/lymphocyte ratio (an
inflammation marker) were predictive of outcome and may
contribute to treatment decisions.
Meaning Decision-making for older and/or frail patients with
advanced cancer can be enhanced using geriatric assessment;
such patients generally benefit from reducing the intensity of
chemotherapy.
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Procedures
The GA, aligned with the European Organization for Re-
search and Treatment of Cancer (EORTC) Elderly Minimum
Data set,12 was administered after consent but before random-
ization; results were not communicated to the clinician. It in-
cluded G8,13 Instrumental Activities of Daily Living (IADL),14
Timed Up and Go test,15 EORTC QLQ-C30/OG25,16,17 and EQ-5D
and visual analogue scale (EQ-VAS).18 Frailty was scored by as-
sessing impairment (yes/no) in nine domains (weight loss, mo-
bility, falls, neuropsychiatric, physical functioning, social func-
tioning, mood, fatigue, and polypharmacy) and participants
were categorized as not frail (0-1/9 domain impaired), mildly
frail (2/9 domains), or severely frail (≥3/9 domains).19
Patients with estimated glomerular filtration rate (eGFR)
of 30 to 50 mL/min or bilirubin 1.5 to 2 times the upper
limit of normal received 75% of their allocated dose of ca-
pecitabine. Patients with ERBB2 (formerly HER2)-positive can-
cers could additionally receive trastuzumab. Imaging was re-
peated every 9 weeks, and chemotherapy stopped in the event
of radiological or clinical progression, unacceptable toxic ef-
fects, or patient choice. Patients allocated to BSC had access
to specialist palliative care, pain and psychosocial services,
blood transfusions, nutritional support, radiotherapy, stent-
ing, or surgical procedures as indicated; chemotherapy,
although not planned, was allowable if it later became
indicated.
Overall Treatment Utility was scored once, 9 weeks after
starting chemotherapy. It comprised computed tomography
(CT) and clinical assessment of cancer progression status; toxic
effects (Common Terminology Criteria for Adverse Events, CT-
CAE) and serious adverse events (SAEs); quality of life (QL, as
scored with QLQ-C30 Global Health Status subscale), and pa-
tient value/acceptability, scored from 2 questions posed in a
questionnaire before patients received their scan results: “Since
you started chemotherapy, how worthwhile do you think your
treatment has been?” and “How much has your chemo-
therapy interfered with your normal daily activities?” both
scored “not at all/a little/quite a bit/very much.” Overall Treat-
ment Utility was not measurable in patients allocated BSC.
Treatment beyond 9 weeks continued until CT progres-
sion or clinical/patient decision. Longitudinal QL comprised
weekly EQ-VAS and every 3 weeks EQ-5D and QLQ-C30 Fa-
tigue Subscale during chemotherapy, then then once every 9
weeks until a year from randomization.
Outcomes
End points, conforming to the joint EORTC/Alliance/
International Society of Geriatric Oncology (SIOG) Statement,20
are defined in the trial protocol (Supplement 1) and statistical
analysis plan (Supplement 2). In the CHEMO-INTENSITY ran-
domization the primary end point was investigator-
determined progression-free survival (PFS).21 The key second-
ary end point was OTU. A score of “Good OTU” requires no
radiological or clinical evidence of cancer progression, no ma-
jor toxic effects (a serious adverse reaction [SAR], or any grade
≥3 non-hematological toxicity), no significant deterioration in
QL (≥16 percentage-points drop in EORTC Global QL subscale22)
and no adverse responses to patient value/acceptability ques-
tions (“not at all” worthwhile or “very much” interference).
Poor OTU denotes evidence of cancer progression and at least
1 other negative factor (toxic effects, SAE, QL deterioration, or
poor value/acceptability), or the patient has died. Intermedi-
ate OTU means either cancer progression without any other
negative factor or negative factors without cancer progres-
sion. Other secondary end points were toxic effects; symp-
toms (QLQ-C30/OG250); QL; RECIST response11; overall sur-
vival (OS); and quality-adjusted survival. Fatigue was scored
using QLQ-C30 with time-to-deterioration from randomiza-
tion to a deterioration of 16 percentage points or more. In the
CHEMO-BSC randomization, the primary end point was OS;
secondary end points were patient-reported fatigue and QL.
Statistical Analysis
In the CHEMO-INTENSITY randomization, reducing the dose of
chemotherapy was hypothesized to provide a better patient ex-
perience without major detriment in PFS. The trial therefore used
a PFS noninferiority design but with a relatively nonstringent
boundary, set following careful discussion at a forum of patients
andclinicians,whereacceptableabsolutePFS/OSlosseswerecon-
sidered as a trade-off against toxicity. Patients were prepared to
sacrifice 6 weeks or more of PFS in return for reduced treatment
toxic effects, but clinicians were more conservative and the trial
was eventually powered to exclude 34 days or greater reduction
in median PFS from a predicted 134 days, equivalent to hazard ra-
tio (HR) at or over 1.34. With 1-sided 5% significance and 80%
power, this required 284 events or more per pairwise compari-
son,requiringrecruitmentof501patientsormore.IntheCHEMO-
BSCrandomization,chemotherapywashypothesizedtoimprove
OS; however, given that the uptake of this randomization was not
predicable at the time of designing the trial, the sample size could
notbepredeterminedandonlyexploratoryanalysiswasplanned.
Efficacy analyses were by intention to treat (ITT); safety
and toxic effect analyses in patients who received 1 or more
dose of protocol therapy. Kaplan-Meier methods were used
to estimate survivor functions for time-to-event end
points.23 Cox proportional hazards regression adjusted for
minimization factors were used to estimate HRs and CIs,
using 1-sided 95% CIs for the noninferiority comparison.24
Proportional hazards were assessed using a permutation
test of martingale residuals. No violations were observed.
Overall Treatment Utility comparisons used ordinal logistic
regression adjusting for minimization factors to estimate
odds ratios (ORs) and 95% CIs.25
For QL subscales, we found no evidence against the miss-
ing-at-random assumption using descriptive and logistic re-
gression analysis, so we applied multiple imputation by
chained equations (MICE).26 We compared allocated groups
for QL and symptom subscales using multiple linear regres-
sion adjusted for the baseline subscale and minimization fac-
tors (excluding center). For fatigue we compared groups using
multilevel repeated mixed-model analyses allowing for time
effects, treatment-time interactions, baseline fatigue (fixed ef-
fects), and patient and patient-time interaction (random ef-
fects). These models were also used to estimate treatment ef-
fects and 95% CI. We performed sensitivity analyses for
complete cases.
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Subgroup analysis used the same model methods as pri-
mary and secondary end point comparisons, prespecified for
potentially prognostic variables: patient characteristics/
minimization factors, frailty, QL/symptoms, and laboratory
tests. Tests for heterogeneity correspond to 1 degree of free-
dom for 2-category subgroups (or continuous scales), 2 de-
grees of freedom for 3-category subgroups, and so on. Follow-
ing univariate analyses with ordinal logistic regression, we
performed multivariable analysis using backward elimina-
tion including all variables, irrespective of univariate result.
Finally, we constructed a nomogram using a transformation
of the linear predictor to a scale estimating the probability of
each OTU outcome.
P values for superiority comparisons are 2-sided and con-
sidered significant at an overall significance level of 5%. All
other analyses are described in the statistical analysis plan
(Supplement 2). For analysis, SAS version 9.4 (SAS Institute)
and R version 3.2.3 (R Project) were used.
Results
A total of 514 patients entered the CHEMO-INTENSITY and
45 entered the CHEMO-BSC randomization, between Janu-
ary 2014 and November 2017, at 61 UK medical centers
(Figure 1; eTable 1 in Supplement 3); cutoff date was Febru-
ary 2019. Slow recruitment in some centers was attributed
to patients opting for the lower dose levels off-trial. Popula-
tions were well-balanced within each randomization but
differed between the two, with CHEMO-BSC patients having
higher rates of poor PS and severe frailty, driven especially
by impaired ADL, low mood and social care requirements
(Table 1; eTable 2 in Supplement 3). Of the total 559
patients, 44 (8%) were neither frail nor aged over 75 years,
reflecting the flexibility of the selection criteria (eTable 3 in
Supplement 3).
CHEMO-INTENSITY Randomization
In the ITT analysis, both lower doses satisfied the prespeci-
fied trial definition of noninferior PFS compared with Level
A; neither CI crosses the HR boundary of 1.34 (Figure 2).
A total of 438 (85%) patients experienced PFS events, with
HR = 1.09 (95% CI, 0.89-1.32) for B vs A and HR = 1.10 (95%
CI, 0.90-1.33) for C vs A. After 373 (73%) deaths, there is no
evidence that higher-dose treatment improved OS: B vs A
HR = 1.09 (95% CI, 0.88-1.36); C vs A HR = 1.14 (95% CI,
0.92-1.41) (Figure 2). No subgroup was identified demon-
strating clear benefit with Level A for either PFS or OS (eFig-
Figure 1. CONSORT Diagrams
514 Patients were randomized in the CHEMO-INTENSITY pathway 
170 Randomized to Level A 171 Randomized to Level B 173 Randomized to Level C 
161 Received Level A 
9 Received no treatment 
163 Received Level B
8 Received no treatment 
168 Received Level C
5 Received no treatment 
170 Included in ITT analysis 171 Included in ITT analysis 173 Included in ITT analysis 
142 Progressed or died 
28 Alive and progression-free 
147 Progressed or died 
24 Alive and progression-free 
149 Progressed or died 
24 Alive and progression-free 
CONSORT diagram for the CHEMO-INTENSITY pathwayA
45 Patients were randomized in the CHEMO-BSC pathway 
23 Randomized to Level C 22 Randomized to BSC 
18 Received Level C 
5 Received no treatment 
23 Included in ITT analysis 22 Included in ITT analysis 
17 Died 
6 Alive 
20 Progressed or died 
2 Alive 
CONSORT diagram for the CHEMO-BSC pathwayB
A, CONSORT diagram for the
CHEMO-INTENSITY pathway. B,
CONSORT diagram for the
CHEMO-BSC pathway. Treatment
pathways are detailed in the
Randomization section of Methods.
BSC indicates best supportive care
alone; ITT, intention to treat.
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ures 1-4 in Supplement 3). Among the 349 (68%) RECIST-
assessable patients there was a lower response rate
(CR/PR) in Level B, but not Level C (B vs A OR = 0.53
[ 9 0 % C I , 0. 3 3 - 0. 8 5 ] ; C v s A H R = 0.6 3 [ 9 0 % C I ,
0.36-1.11]), with little difference in disease control (CR/PR/
SD) (eTable 11 in Supplement 3). Results for PFS were similar
in the per-protocol analysis (n = 492), with HR = 1.09 (95%
CI, 0.89-1.34) for B vs A and HR = 1.10 (95% CI, 0.90-1.34)
for C vs A (eFigure 13 in Supplement 3).
Overall Treatment Utility, assessed in all 514 patients by
ITT, was good in 196 patients (38%), intermediate in 149
(29%), and poor in 169 (33%). Level C produced more good
(43%) and fewer poor (29%) OTU outcomes than A or B, but
these differences were not statistically significant (eFigure 1
in Supplement 3). Other patient experience end points also
trended toward better outcomes with lower doses
(eTables 4-9 in Supplement 3). Time-to-deterioration of
fatigue favored Level C (C vs A HR = 0.88 [95% CI, 0.65-
1.19]). Global QL (EORTC Core Quality of Life questionnaire,
QLQ-C30, and EuroQoL-5 Dimension, EQ-5D) improved
between baseline and 9 weeks with Levels B and C, but not
A (eFigures 4-7 in Supplement 3). Longitudinal fatigue and
QL showed no major differences. Cancer symptoms
improved between baseline and 9 weeks in all arms simi-
larly (eFigures 8-12 in Supplement 3).
The rate of toxic effects fell markedly with reducing
dose levels (Table 2). Consequently, treatment delivery was
more reliable: during the first three 3-week cycles, compar-
ing Levels A, B, and C, a dose reduction was required in 63
(39%), 39 (24%), and 21 (13%) patients, respectively; 53
Table 1. Baseline Patient Characteristics
Treatment allocation
No. (%)








(n = 23) BSC (n = 22)
Age, median (range), y 76 (57-96) 76 (51-91) 77 (56-88) 79 (66-89) 78.5 (58-88)
Male gender 131 (77) 129 (75) 125 (72) 14 (61) 13 (59)
WHO performance status
0 27 (16) 23 (13) 22 (13) 0 0
1 90 (53) 94 (55) 95 (55) 9 (39) 6 (27)
2 49 (29) 47 (27) 52 (30) 11 (48) 14 (64)
>2 3 (1.8) 7 (4.1) 3 (1.7) 3 (13) 2 (9.1)
Frailty
Not frail (0-1 domains) 23 (14) 30 (18) 41 (24) 2 (8.7) 1 (4.5)
Slightly frail (2 domains) 44 (26) 45 (26) 32 (18) 5 (22) 6 (27)
Severely frail (≥3 domains) 103 (61) 96 (56) 100 (58) 16 (70) 15 (69)
Frailty/age
Age ≥75 y and frail 74 (44) 81 (47) 71 (41) 15 (65) 16 (73)
Age ≥75 y and nonfrail 16 (9) 15 (9) 20 (12) 1 (4) 1 (4)
Age <75 y and frail 73 (43) 60 (35) 61 (35) 6 (26) 5 (23)
Age <75 y and nonfrail 7 (4) 15 (9) 21 (12) 1 (4) 0
Squamous histology 20 (12) 18 (11) 20 (12) 4 (17) 5 (23)
Site of primary tumor
Esophagus 55 (32) 73 (43) 69 (40) 13 (57) 9 (49)
GO junction 50 (29) 34 (20) 39 (23) 4 (17) 4 (18)
Gastric 64 (38) 64 (37) 64 (37) 6 (26) 9 (41)
Distant metastases 115 (68) 118 (69) 121 (70) 11 (48) 10 (46)
Trastuzumab use 7 (4.1) 10 (5.8) 10 (5.8) 0 0
Individual domains contributing
to the Frailty Scoreb
BMI<18.5 7 (4.1) 13 (7.6) 11 (6.4) 2 (8.7) 6 (27)
Weight loss 92 (54) 94 (55) 85 (49) 11 (48) 10 (45)
Mobility (TUGT) 103 (61) 91 (53) 95 (55) 19 (83) 14 (64)
Falls 8 (4.7) 9 (5.3) 7 (4.0) 2 (8.7) 0
Cognition 22 (13) 25 (15) 26 (15) 4 (17) 3 (14)
Function (ADL) 97 (57) 97 (57) 100 (58) 16 (70) 19 (86)
Social care 0 2 (1.2) 1 (0.6) 23 (100) 21 (95)
Mood 2 (1.2) 4 (2.3) 3 (1.7) 21 (91) 22 (100)
Fatigue 42 (25) 42 (25) 42 (24) 5 (22) 7 (32)
Polypharmacy 127 (75) 129 (75) 116 (67) 19 (83) 14 (64)
Abbreviations: ADL, activities of daily
living; BMI, body mass index; WHO,
World Health Organization; TUGT,
Timed Up and Go Test. BMI is
calculated as weight in kilograms
divided by height in meters squared.
a Treatment pathways are detailed in
the Randomization section of
Methods.
b For frailty definitions, see the trial
protocol (Supplement 2).
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(33%), 47 (29%), and 34 (20%) patients stopped treatment
wholly or partly owing to toxicity, and 51 (32%), 72 (44%),
and 97 (58%) patients respectively completed their first 3
cycles without reduction or stoppage (eTable 15 in Supple-
ment 3). Mean (SD) treatment duration was 4.4 (3.3), 4.6
(4.0), and 5.4 (4.1) cycles, respectively, and 30 (18%), 36
(21%), and 47 (27%) went on to receive 6 or more cycles.
Second-line therapy was recorded in 23 (14%), 18 (11%), and
24 (14%) patients.
CHEMO-BSC Randomization
A total of 45 patients entered the CHEMO-BSC randomiza-
tion. In those allocated chemotherapy, toxicity was higher than
in patients allocated the same dose level in the CHEMO-
Figure 2. Survival Curves
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C, CHEMO-BSC overall survival.
Treatment pathways are detailed in
the Randomization section of
Methods. BSC indicates best
supportive care alone.
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INTENSITY randomization (Table 2). Longer OS was ob-
served with chemotherapy than with BSC, but the difference
was not statistically significant (HR = 0.69 [95% CI, 0.35-
1.48]). Both QL and fatigue were nonsignificantly better with
chemotherapy than BSC (eFigure 8 and eFigure 9 in
Supplement 3).
Baseline Predictors of OTU
Univariate analysis in all 537 patients allocated chemo-
therapy identified the following baseline factors associated
with worse OTU (P ≤ .05): distant metastases, raised B-type na-
triuretic peptide (BNP) or N-terminal prohormone of brain na-
triuretic peptide (NT-proBNP), leukocytosis, raised neutro-
phil to lymphocyte ratio (NLR), hypoalbuminaemia, raised
urea, severe frailty (dementia, activities of daily living [ADL],
and polypharmacy domains), poor global QL, and impaired
taste (eFigure 1 in Supplement 3).
In multivariable analysis, baseline frailty, EQ5D-VAS, and
NLR were independently associated with OTU. These factors
can be used to calculate a predictive score: (0.27 if not se-
verely frail) + (0.39 if EQ-VAS ≥ 50) + (0.34 if NLR ≤ 4.0). This
score (range 0-1) translates into the probability of good, inter-
mediate, or poor OTU at 9 weeks (eTable 10 and eTable 11 in
Supplement 3). Thus, a slightly frail patient with baseline EQ-
VAS = 55 and NLR = 3.0 (predictive score = 1) has a 44% prob-
ability of good and 27% probability of poor OTU. Conversely,
a severely frail patient with baseline EQ-VAS = 45 and NLR = 5.0
(score = 0) has only 18% probability of good OTU but 57% prob-
ability of poor OTU.
In the CHEMO-INTENSITY randomization (n = 514), in-
teraction was seen between the multivariable predictive score
and dose level (P = .01) with greater incremental benefit of
lower-dose treatment in patients with better baseline scores:
thus a patient with score = 1 allocated to Level C has 68% prob-
ability of good, 20% intermediate, and 12% poor OTU, but if
the same patient is allocated Level A these probabilities are 41%,
30%, and 29%. No baseline score was identified as predicting
better OTU with higher-dose treatment (eTables 12-14 in
Supplement 3).
Discussion
The GO2 randomized clinical trial is the first large trial testing
the relationship between treatment intensity and patient-
focused outcomes in frail and/or older patients with cancer.
Previous reports have studied older patients who were fit
enough to enter all-comer trials,27 or relied on traditional ef-
ficacy and safety end points.28 The GO2 trial uses modern
methods and studies patients—the older frail, older nonfrail,
and younger frail—who rarely participate in trials. In re-
sponse to calls to address the deficit in evidence guiding treat-
ment of vulnerable cancer patients,29 we offer GO2 as an ex-
emplar of real-world, patient-centered research.
Lower-dose chemotherapy improved patients’ experi-
ence without compromising anticancer control. This balance
is captured in OTU, an objective measure of a virtual conver-
sation between physician and patient and reflecting their joint
assessment of treatment value: “With the benefit of hind-
sight, am I glad I recommended this treatment?” and “Am I glad
that I accepted it?” The GO2 trial also demonstrates that a base-
line GA can contribute to the doctor-patient decision by esti-
mating an individual’s probability of better or worse OTU.
In designing GO2, decisions were necessary for patient se-
lection, treatment, and statistical design, all of which may be
debated. For example, previous trials could not characterize
patients who were not included, but it was precisely those pa-
tients who were to be selected for GO2. It was therefore nec-




Level A (n = 162) Level B (n = 162) Level C (n = 168) Level C (n = 18)
Max CTCAE grade (week 1-9)b ≥2 ≥3 ≥2 ≥3 ≥2 ≥3 ≥2 ≥3
Nausea or vomiting 47 (29) 14 (8.6) 33 (20) 8 (4.9) 29 (17) 12 (7.1) 2 (11) 0
Anorexia 45 (28) 11 (6.7) 46 (28) 14 (8.6) 32 (19) 3 (1.8) 13 (17) 0
Diarrhea 34 (21) 10 (6.2) 19 (12) 10 (6.2) 7 (4.2) 3 (1.8) 1 (5.6) 1 (5.6)
Peripheral neuropathy 24 (15) 4 (2.5) 11 (6.7) 1 (0.6) 6 (3.6) 1 (0.6) 2 (11) 0
Fatigue 86 (53) 24 (15) 72 (44) 20 (12) 67 (40) 18 (11) 6 (33) 4 (22)
Infection 7 (4.3) 4 (2.5) 15 (9.3) 9 (5.6) 5 (3.0) 1 (0.6) 0 0
Thrombosis 5 (3.1) 5 (3.1) 4 (2.5) 3 (1.9) 3 (1.8) 2 (1.2) 2 (11) 2 (11)
Any nonhematologicalc 125 (77) 62 (38) 116 (72) 58 (36) 101 (60) 38 (23) 10 (56) 7 (39)
WBC/neutrophils (×109/l) 10 (6.2) 1 (0.6) 3 (1.9) 0 5 (3.0) 1 (0.6) 0 0
Anaemia 26 (16) 1 (0.6) 33 (20) 6 (3.7) 22 (13) 3 (1.8) 2 (11) 0
Any hematologicald 33 (20) 3 (1.9) 36 (22) 6 (3.7) 27 (16) 4 (2.4) 2 (11) 0
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; WBC,
white blood cell count.
a Treatment pathways are detailed in the Randomization section of Methods.
b Maximum CTCAE grade experienced weeks 1-9 in patients receiving 1 cycle
of their allocated chemotherapy. Individual listings are shown for more
common toxic effects.
c “Any nonhematological” is defined as any of the following: nausea, vomiting,
anorexia, stomatitis, diarrhea, hand-foot syndrome, peripheral neuropathy,
fatigue, infection, thrombosis, or dehydration.
d “Any hematological” is defined as any of the following: low white blood cell
count, low neutrophils/granulocytes, low platelets, or anemia.
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essary to use clinicians’ experience, rather than an objective
tool, to offer trial entry to patients they assessed as unsuited
to full-dose combination chemotherapy but able to receive re-
duced-intensity treatment.
Even the highest dose in GO2, Level A, was less-than-
standard treatment, comprising just 2 drugs from the stan-
dard EOCap triplet.2 Although this includes full-dose oxalipl-
atin, it is combined with low-dose continuous capecitabine
rather than the intensive intermittent schedule typically used
in doublet therapy. Level C therefore represents just 60% of 2
out of 3 drugs, around 40% of full standard dose intensity. It
is also important to recognize that Level A, although a refer-
ence schedule for this trial, is not standard therapy; indeed,
the stimulus for the trial was a survey showing that there is
no standard for this population.7 For this reason we did not ap-
ply the typical stringent noninferiority boundary demanded
by regulators, but were instead able to work with patients and
clinicians to carefully balance the competing needs for can-
cer control and good tolerability.
One mechanism for retaining cancer control despite lower
doses is avoidance of toxicity-induced treatment reductions
and stoppages. Toxic effects leading to treatment modifica-
tion may be accepted by oncologists as part of standard on-
cology practice, but it represents a negative experience for pa-
tients and detracts from both quality of life and cancer control;
and these impacts are particularly heightened in patients with
poor baseline reserve. Only 32% patients starting Level A were
able to receive 3 cycles without reduction or stoppage, com-
pared with 58% with Level C.
TheGO2trialaimedtodevelopdoseindividualizationguided
by baseline geriatric assessment: we anticipated fitter patients
would benefit from higher-dose treatment; however, we did not
identify any group for whom the higher doses are preferable.
Using the OTU outcome measure, reflecting the balance of ben-
efits and harms, goes beyond conventional single-outcome mod-
els looking at survival or toxicity in isolation.30 In so doing, GO2
challenges a pervading assumption of oncology: that within the
bounds of tolerability more is better. We hope it will stimulate
research exploring lower-dose chemotherapy, perhaps extend-
ing to younger and less frail patients. We hope also that those
designing trials of novel agents, including registration studies,
will consider the option of lower-dose chemotherapy as the ref-
erence or platform to which novel agents are added, to widen
access to these trials.
The 3-month survival benefit seen in the CHEMO-BSC ran-
domization, though nonsignificant in isolation as a conse-
quence of small numbers and an imbalance in patient charac-
teristics, concurs with previous data31 and supports
consideration of low-dose chemotherapy in vulnerable pa-
tients. This should, however, be interpreted alongside the base-
line predictor, which helps identify patients at high risk of poor
treatment utility, for whom BSC may be a preferable path.
Limitations
A limitation of GO2 is that our GA was purely observational.
Implementation of these findings—and future research—
should embrace the newer concept of Comprehensive Geri-
atric Assessment (CGA): both identification of vulnerabilities
and active remedial management to correct them. An out-
standing research question is whether CGA-based pre-
habilitation will convert a patient from low to high probabil-
ity of achieving good OTU.
Conclusion
The GO2 clinical trial shows that the goals of palliative che-
motherapy in the older and/or frail population, including but
not limited to cancer control, may be better achieved using
treatment at doses well below those currently regarded as stan-
dard. Careful baseline geriatric health assessment in the on-
cology clinic can help predict the likelihood of achieving those
goals, and so contribute to patients’ and clinicians’ treatment
decisions. Assessing the outcome of cancer treatment should
be multidimensional, including its value to patients and its ad-
verse effects, and we recommend further development of OTU
to capture this complexity. The GO2 trial offers a design para-
digm for enhancing older patients’ access to research and en-
suring that our evidence base embraces the whole popula-
tion that we serve.
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